Patents by Examiner Stuart W. Snyder
  • Patent number: 9750800
    Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: September 5, 2017
    Assignee: Sanofi Pasteur SA
    Inventors: Virginie Fabre, Celine Rocca, Pierre Riffard, Eric Calvosa
  • Patent number: 9744229
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: August 29, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Mathew P. Morrow
  • Patent number: 9745352
    Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: August 29, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Rahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
  • Patent number: 9738688
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 22, 2017
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
  • Patent number: 9732327
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 15, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
  • Patent number: 9732121
    Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 15, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
  • Patent number: 9725485
    Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 8, 2017
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
  • Patent number: 9719127
    Abstract: The invention pertains to a novel cell line, an HIV tat-rev dependent GFP-Gaussia luciferase Reporter cell line, known henceforth as the GGR cell line, that detects pseudotype and replication competent HIV (cloned or uncloned isolates, in cell media or human serum) rapidly and with high sensitivity. This GGR cell line provides an improved method of characterizing the entry phenotype of HIV envelope genes, and detecting and examining primary HIV samples in the context of laboratory research, clinical trial monitoring, and medical diagnostics. Examples include, but are not limited to, determining the functional HIV viral load, responsiveness to treatment, characterization of viral co-receptor usage (testing for viral co-receptor usage, i.e., CCR5 vs CXCR4, as required prior to prescribing FDA-approved CCR5 inhibitors), and characterization of other viral or drug resistance phenotypic properties to guide treatment.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 1, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Benhur Lee, Kelechi Chikere, Tom Chou
  • Patent number: 9714420
    Abstract: Methods and systems for purifying cells and/or viruses are provided. The sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the cells and/or viruses in the well. The cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the cells and/or viruses may be retained in the well by embedding in the medium. The medium including the embedded cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: July 25, 2017
    Assignee: Accelerate Diagnostics, Inc.
    Inventors: Steven W. Metzger, Kenneth Robert Hance
  • Patent number: 9688729
    Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 27, 2017
    Assignee: CureVac AG
    Inventors: Thomas Kramps, Margit Schnee, Daniel Voss, Benjamin Petsch
  • Patent number: 9687515
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 27, 2017
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9687547
    Abstract: The present invention concerns methods and compositions for treatment of HIV infection using a T20 expression vector, such as that shown in SEQ ID NO:1 or SEQ ID NO:3. The T20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to HIV, localized transfection in vivo in a gene therapy approach to provide longer term delivery of T20, or in vitro production of T20 peptide. The T20 may be secreted into the circulation to act as a fusion inhibitor of HIV infection, or may induce an endogenous immune response to HIV or HIV-infected cells. Alternatively, a DDD peptide may be incorporated in a fusion protein comprising T20 or another antigenic protein or peptide to enhance the immune response to the protein or peptide.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: June 27, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Sofia Stenler, Britta Wahren, Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 9689873
    Abstract: The present invention provides a method using immunoassay devices to differentiate infection with HIV-2 from infection with both HIV-1 and HIV-2 in a subject.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: June 27, 2017
    Assignee: BIO-RAD INNOVATIONS
    Inventor: Pierre Chaumat
  • Patent number: 9688965
    Abstract: A recombinant neuraminidase based on amino acid sequence (SEQ ID NO: 1) of wild-type pH1N1-NA (A/Texas/05/2009) influenza virus is provided. The recombinant neuraminidase of the present invention has an ectodomain with an amino acid sequence identical to SEQ ID NO: 1 and replaced at specific positions 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses. The recombinant neuraminidase may incur cross-protective immunity and be used as universal influenza vaccine.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: June 27, 2017
    Assignee: National Tsing Hua University
    Inventors: Suh-Chin Wu, Wen-Chun Liu, Chia-Ying Lin
  • Patent number: 9688744
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 27, 2017
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Patent number: 9682138
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 20, 2017
    Assignee: MERIAL, INC.
    Inventors: Herve Poulet, Thierry Heidmann
  • Patent number: 9682136
    Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: June 20, 2017
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Chaouki Miled, Frédéric Tangy, Yves Jacob
  • Patent number: 9670253
    Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: June 6, 2017
    Assignees: Beth Israel Deaconess Medical Center, Inc., Los Alamos National Security, LLC
    Inventors: Dan H. Barouch, Bette T. Korber, William M. Fischer
  • Patent number: 9663556
    Abstract: Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 30, 2017
    Assignee: PIN Pharma, Inc.
    Inventors: Joshua Goldberg, Colin Bier
  • Patent number: 9662385
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 30, 2017
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, Jr., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi